Compare BCG & GBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BCG | GBIO |
|---|---|---|
| Founded | 2016 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.6M | 35.4M |
| IPO Year | N/A | 2020 |
| Metric | BCG | GBIO |
|---|---|---|
| Price | $1.99 | $5.30 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $10.67 |
| AVG Volume (30 Days) | ★ 2.0M | 40.1K |
| Earning Date | 11-13-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.04 | N/A |
| Revenue | ★ $178,203,000.00 | $15,270,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $57.50 | ★ N/A |
| Revenue Growth | ★ 10.19 | N/A |
| 52 Week Low | $1.36 | $3.00 |
| 52 Week High | $6.00 | $13.00 |
| Indicator | BCG | GBIO |
|---|---|---|
| Relative Strength Index (RSI) | 46.39 | 50.63 |
| Support Level | $2.33 | $5.22 |
| Resistance Level | $3.07 | $5.64 |
| Average True Range (ATR) | 0.33 | 0.24 |
| MACD | -0.06 | 0.05 |
| Stochastic Oscillator | 8.32 | 59.32 |
Binah Capital Group Inc formerly Wentworth Management Services LLC is a holding company that acquires and manages businesses in the wealth management industry. The company specializes in consolidating independent broker-dealers to capture economies of scale needed to service financial advisors in today's technology-enabled regulatory environment. Wentworth's core philosophy focuses on building long-term, productive relationships with its advisor base.
Generation Bio Co is a genetics medicine company focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable differentiated therapeutic applications. Its first platform is a potent, selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.